NCT07046806View on ClinicalTrials.gov

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Hereditary Angioedema (HAE)AngioedemaBradykinin-mediated AngioedemaC1 Inhibitor Deficiency
Interventions
DRUG

Deucrictibant XR tablet

Deucrictibant 40 mg XR tablet for prophylaxis

DRUG

Placebo comparator to XR tablet

Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis

DRUG

Deucrictibant 20 mg capsule

Deucrictibant active drug for on-demand treatment of angioedma attacks

DRUG

Placebo comparator to 20 mg capsule

Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks

Trial Locations (1)

20902

RECRUITING

Institute For Asthma & Allergy, Wheaton

All Listed Sponsors
lead

Institute for Asthma and Allergy

NETWORK